Dietary Supplement cGMP Online Training | 21 CFR Part 111 | Early Registration Now Open
There have been no major structural changes to 21 CFR Part 111 in recent years. However, focusing on regulatory updates alone misses the more important shift taking place across the dietary supplement industry.
In 2026, the risk is not new regulation — it is enforcement.
Regulators are no longer primarily concerned with how companies interpret cGMP requirements. Instead, the focus has shifted toward whether those requirements are being consistently implemented, documented, and maintained in practice. Based on recent inspection trends and warning letters, this is where many organizations are falling short.
For many years, cGMP compliance has been approached as something to prepare for — an exercise triggered by an upcoming inspection or regulatory milestone. That approach is increasingly misaligned with how oversight is now being conducted.
Inspection activity continues to increase, yet still covers only a small portion of registered facilities. As a result, FDA is applying a more targeted, risk-based approach, prioritizing companies with complex operations, limited inspection history, or known compliance concerns .
At the same time, the expansion of unannounced inspections, particularly for foreign manufacturers, has removed the ability to prepare in advance . This shift reinforces a new baseline expectation: companies must be operating in a compliant state at all times, not just when an inspection is anticipated.
While the regulatory framework itself remains stable, enforcement has become increasingly concentrated on a set of well-established compliance gaps. These are not new requirements, but they are being applied with greater scrutiny and less tolerance.
One of the most common issues cited in warning letters is the failure to establish adequate specifications for identity, purity, strength, and composition. These specifications form the foundation of product quality under 21 CFR Part 111, and without them, companies cannot demonstrate that their products meet regulatory expectations .
Equally significant are deficiencies in manufacturing documentation. FDA findings frequently identify the absence of master manufacturing records, incomplete or missing batch production records, and inconsistencies in documentation practices. Without complete and accurate records, it becomes impossible to demonstrate that products are manufactured under controlled conditions.
FDA has made clear that, for dietary ingredients, reliance on a supplier Certificate of Analysis alone is not sufficient to satisfy identity requirements; manufacturers are generally expected to perform at least one appropriate identity test on each lot unless an exemption has been granted. In addition, many firms are unable to demonstrate that quality control functions are properly defined and executed. Warning letters frequently cite the absence of written procedures, unclear responsibilities, and inadequate oversight of quality-related decisions. This lack of structure undermines the integrity of the entire quality system.
Labeling compliance also remains a persistent issue, with misbranding violations tied to missing or incorrect information, unsupported claims, and failure to include required statements or disclaimers. These findings often accompany broader cGMP deficiencies and can independently lead to enforcement action.
Finally, and perhaps most critically, companies often fail to demonstrate that personnel are adequately trained and qualified. Under 21 CFR Part 111, this is not a secondary consideration — it is a core requirement tied directly to compliance.
These deficiencies are not isolated to specific companies or segments of the industry. They appear consistently across FDA inspections, indicating a broader pattern rather than individual oversight.
In practice, most organizations are not failing because they lack awareness of the regulations. They are failing because they are unable to translate those requirements into consistent, documented execution within their operations.
This distinction is critical. cGMP compliance is not achieved through documentation alone; it requires a functioning system that is actively implemented and maintained across all aspects of production and quality oversight.
The regulatory environment is not the only source of pressure. Several additional trends in 2026 are reinforcing the need for stronger compliance systems.
The use of unannounced inspections has reduced the margin for error, particularly for companies operating internationally. At the same time, FDA is placing greater emphasis on supply chain accountability, including supplier qualification and raw material verification.
FDA has indicated that further clarification on New Dietary Ingredient (NDI) notifications is coming in 2026, adding to the broader expectation that firms maintain stronger safety and identity support from development through commercialization.
Beyond regulatory oversight, commercial requirements are also evolving. Major retailers are increasingly requiring proof of cGMP compliance as a condition for market access. Amazon, for example, now requires third-party verification of cGMP compliance for dietary supplements, with limited timelines to provide documentation or risk removal from the platform .
Taken together, these trends indicate that compliance is no longer solely a regulatory obligation — it is becoming a prerequisite for doing business.
When inspections result in findings, the root cause is rarely a lack of written procedures. More often, the issue lies in how those procedures are implemented and maintained.
Common breakdowns include inconsistent execution, incomplete documentation, unclear responsibilities, and a lack of alignment between documented processes and actual operations. In many cases, personnel are not fully equipped to interpret and apply cGMP requirements within their roles.
This highlights a fundamental reality: cGMP compliance is not a static set of documents, but a system of execution that depends on people, processes, and oversight working together.
Under 21 CFR Part 111, companies are required to ensure that personnel are qualified through appropriate education, training, or experience. This includes training in cGMP principles relevant to their responsibilities, as well as maintaining documentation to demonstrate compliance.
In practice, this is one of the most common areas of weakness. Training is often informal, inconsistently delivered, or not aligned with current regulatory expectations. In many cases, it is not documented in a way that supports inspection readiness.
As enforcement intensifies, training is taking on a more central role. It is no longer simply a supportive activity, but a key component of a defensible quality system. Effective training enables personnel to execute procedures correctly, maintain proper documentation, and respond confidently during inspections.
Dietary Supplement cGMP Online Training | 21 CFR Part 111
To address these challenges, dicentra has developed a structured cGMP training program designed specifically for dietary supplement operations. The program is built to support ongoing compliance by aligning training with real-world regulatory expectations and operational requirements.
The training provides comprehensive coverage of 21 CFR Part 111 (Subparts A–P), ensuring a complete understanding of the regulatory framework. It incorporates practical scenarios based on actual inspection findings, helping participants understand how requirements are applied in practice.
Designed for professionals across quality assurance, regulatory affairs, and manufacturing operations, the program supports both onboarding and refresher training. Its online format allows for flexible, self-paced learning, while built-in quizzes and assessments reinforce understanding and retention.
Participants receive a personalized certificate upon successful completion, supporting internal documentation requirements and demonstrating compliance during audits and inspections. With 12-month access and periodic refresher content, the program is structured to support ongoing compliance rather than one-time training.
Pre-registration is currently open for the upcoming training launch, with early-bird pricing available until April 30, 2026.
Organizations that register in advance can secure a 25% discount, with per-user pricing available for smaller teams and enterprise options for larger organizations.
The regulatory framework governing dietary supplements has not undergone significant change. However, the way it is being enforced has evolved.
Companies that continue to treat cGMP compliance as a static requirement may find themselves unprepared for increased scrutiny. In contrast, those that invest in execution, training, and system-wide consistency will be better positioned to meet regulatory expectations and maintain market access.